Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration (NCT05315700)
An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (42 Sites)
Showing the first 25 of 42 sites.
- City of Hope — Duarte, California
- City of Hope — Huntington Beach, California
- City of Hope — Irvine, California
- City of Hope — Long Beach, California
- University of California, San Francisco — San Francisco, California
- Yale Cancer Center — New Haven, Connecticut
- Georgetown University — Washington D.C., District of Columbia
- Mayo Clinic — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
- Northwestern University — Chicago, Illinois
- Dana Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- NYU Langone Health Perlmutter Cancer Center — New York, New York
- Duke Cancer Institute — Durham, North Carolina
- University of Pennsylvania — Philadelphia, Pennsylvania
- Spartanburg Regional Healthcare System — Spartanburg, South Carolina
- Next Oncology — Fairfax, Virginia
- Chris O'Brien Lifehouse — Camperdown,
- Peter MacCallum Cancer Centre — Melbourne,
- One Clinical Research, Hollywood Medical Centre — Nedlands,
- Sydney Adventist Health — Sydney,
- Princess Margaret Cancer Centre — Toronto, Ontario
- The Chinese University of Hong Kong — Shatin,
- Sultan Ahmad Shah Medical Centre at International Islamic University Malaysia (IIUM) — Kuantan, Pahang
- Pulau Pinang Hospital — George Town, Pulau Pinang
📞 Contact the Study Coordinator
Phone: (650) 388-5600
Email: clinical@oricpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.